Over-expression of extracellular matrix metalloproteinase inducer in prostate cancer is associated with high risk of prostate-specific antigen relapse after radical prostatectomy

Xue-cheng Bi; Jiu-Min Liu; Xiang-guang Zheng; Zhi-Yong Xian; Zi-Wei Feng; Yao-Xiong Lou; Wei-de Zhong; Chin-lee Wu
December 2011
Clinical & Investigative Medicine;Dec2011, Vol. 34 Issue 6, p358
Academic Journal
Purpose: The prognostic efficiency of clinical grading and staging in patients with confined or moderately differentiated prostate cancer (PCa) has been markedly improved, which underscores the importance of new prognostic markers. Extracellular matrix metal-loproteinase inducer (EMMPRIN) has been demonstrated to be involved in cancerangiogenesis, metastasis and invasion. EMMPRIN expression was evaluated by measuring mRNA and protein levels in a large cohort of patients with PCa following prostatectomy and the findings were compared with clinico-pathological parameters, including prostatespecific antigen (PSA) relapse time. Methods: EMMPRIN mRNA levels in 20 pairs of normal and cancerous prostate tissues were determined by quantitative real-time PCR. Protein expression in parafin-embedded specimens of prostates gathered from 300 patients with PCa was detected by immunohistochemistry using a monoclonal antibody against EMMPRIN. The associations of EMMPRIN protein expression with the clinico-pathological parameters and PSA relapse-free time after radical prostatectomy were subsequently assessed. Results: Both EMMPRIN mRNA and protein levels were higher in PCa tissue, compared with adjacent normal tissue. In addition, the positive expression rates of EMMPRIN in PCa tissues were significantly associated with preoperative PSA levels (p=0.008), AJCC stage (p=0.006) and Gleason Score (p<0.001), Risk classification (p<0.001), lymph node status post-surgery (p<0.001) and surgical margin status (p<0.001) were also determined. Multivariate analysis, using the Cox proportional hazards model, revealed that positive EMMPRIN expression was an independent prognostic factor for an increased risk of PSA relapse. Conclusion: Over-expression of EMMPRIN correlated with the aggressiveness of PCa, and the PSA relapse-free time, and may be a novel and useful biomarker for follow-up and treatment decisions for PCa.


Related Articles

  • Surgery failed to reduce mortality from PSA-detected prostate cancer.  // Hem/Onc Today;9/10/2012, Vol. 13 Issue 17, p30 

    The article discusses a study led by Timothy J. Wilt of the Center for Chronic Disease Outcomes Research which reveals that radical prostatectomy failed to reduce mortality in patients diagnosed with early-stage prostate cancer after prostate-specific antigen (PSA) testing came into practice.

  • PSA cutoffs no longer valid to determine biopsy. Overmyer, Mac // Urology Times;8/15/2005, Vol. 33 Issue 10, p34 

    Reports on a study questioning the value of established prostate specific antigen (PSA) cutoff points as a means of determining the need to conduct biopsies for prostate cancer. PSA biopsy thresholds used in prostate cancer detection; Argument that the lower the PSA, the better the results are...

  • Local therapy for prostate-specific antigen recurrence after definitive treatment. Meng, M V; Carroll, P R // Prostate Cancer & Prostatic Diseases;2001, Vol. 4 Issue 1, p20 

    Disease recurrence after local therapy for prostate cancer is increasingly common, most often with detectable or rising prostate-specific antigen (PSA) the earliest sign. Analysis of clinical and pathological factors can help determine which patients are at risk for treatment failure, while PSA...

  • Outcomes of extremely low risk prostate cancer following radical prostatectomy. Lee, E W; Laze, J; Lepor, H // Prostate Cancer & Prostatic Diseases;2011, Vol. 14 Issue 3, p266 

    The optimal management of men with very favorable clinicopathological factors who develop biochemical recurrence (BCR) after radical prostatectomy (RP) has not been previously reported. Both local and systemic recurrences are unlikely in this cohort. This study examines their management and...

  • pT3 PROSTATE CANCER. Akduman, Bulent; Crawford, David // Contemporary Urology;Apr2006, Vol. 18 Issue 4, p26 

    Offers criteria for use in determining which men with pathologic stage T3 disease and rising prostate-specific antigen (PSA) levels after radical prostatectomy (RP) can be offered adjuvant radiotherapy. Characteristics predictive of having an undetectable serum PSA level at 10 years in patients...

  • Diagnosticul ÇŽi tratamentul cancerului de prostatâ în stadiul localizat. Ambert, V.; Braticevici, B.; Damian, D.; Chira, I.; Jinga, V.; Iconaru, V.; Radu, T.; Constantin, T. // Romanian Journal of Urology;Sep2010, Vol. 9 Issue 3, p23 

    Introduction: The discovery of prostate specific antigen (PSA) and the use of serum markers represented a step forward in the diagnosis of prostate cancer (PC). Based on substantial clinical experience in diagnosis and treatment of PC (1442 PC cases admitted in our clinic during 2005-2009 and...

  • PSADT Predicts Post RP Death.  // Renal & Urology News;Apr2010, Vol. 9 Issue 4, p20 

    The article presents a study, conducted by Emmanuel S. Antonarakis of Johns Hopkins University in Baltimore, Maryland, which shows that prostate-specific antigen doubling time (PSADT) is the most significant predictor of 15-year overall survival in men experiencing biochemical recurrence after...

  • Surgery favored in men with screen-detected PCa. Guttman, Cheryl // Urology Times;Sep2002, Vol. 30 Issue 9, p8 

    Discusses results of a study favoring radical prostatectomy in men with screen-detected prostate cancer. Patient characteristics; Prostate-specific antigen progression-free rate; Predictors of increased risk of progression.

  • Prostate specific antigen levels in the follow up of localised prostate cancer: how does radiotherapy compare to radical prostatectomy? Ziade, J; Leprise, E S; Bansard, J Y; Patard, J J; Lobel, B; Guille, F // Prostate Cancer & Prostatic Diseases;1999, Vol. 2 Issue 3, p155 

    This study aimed to evaluate tumor progression as assessed by PSA level of curative treatment for localised prostate cancer by either radiotherapy or prostatectomy. From 1987 to 1993, 180 patients were treated for clinically localised prostate cancer either by radiotherapy or prostatectomy. One...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics